Aglietta, Massimo
Chiarion-Sileni, Vanna http://orcid.org/0000-0001-9191-9124
Fava, Paolo http://orcid.org/0000-0002-8443-7458
Guidoboni, Massimo http://orcid.org/0000-0001-7703-790X
Depenni, Roberta
Minisini, Alessandro
Consoli, Francesca
Ascierto, Paolo
Rinaldi, Gaetana
Banzi, Maria
Marconcini, Riccardo
Gueli, Rossana http://orcid.org/0000-0002-2674-6594
Ferraresi, Virginia http://orcid.org/0000-0001-6419-1668
Tucci, Marco
Tonini, Giuseppe http://orcid.org/0000-0003-4442-8677
Lo Re, Giovanni
Guida, Michele
Del Vecchio, Michele http://orcid.org/0000-0001-9060-2512
Marcon, Ilaria Gioia
Queirolo, Paola
Funding for this research was provided by:
novartis farma s.p.a.
Article History
Accepted: 11 October 2021
First Online: 10 November 2021
Declarations
:
: This study was sponsored by Novartis Farma S.p.A. As of 2 March 2015, dabrafenib and trametinib have become assets of Novartis AG. Financial support for medical editorial assistance was provided by Novartis Farma S.p.A.
: Vanna Chiarion-Sileni reports participation as a consultant for Bristol Myers Squibb (BMS), Merck Serono, Novartis, and Pierre Fabre; participation as an invited speaker for Merck Serono, Merck Sharp & Dohme (MSD), Novartis, Pierre Fabre, and Sanofi; and travel and accommodation support from BMS and Pierre Fabre outside the submitted work. Massimo Guidoboni received personal fees for participation in advisory boards from BMS and Novartis; travel support and consultation fees from Pierre Fabre; and a grant from MSD outside the submitted work. Roberta Depenni received grants from BMS, MSD, Novartis, and Sanofi outside the submitted work. Alessandro Minisini reports personal fees from Merck, MSD, Novartis, Pierre Fabre, Sanofi, and Sun Pharma outside the submitted work. Francesca Consoli reports personal fees for advisory board and consultancy from BMS, MSD, Novartis, and Pierre Fabre outside the submitted work. Paolo Ascierto received grants/research funds from Array, BMS, Roche-Genentech, and Sanofi; personal fees for a consultant/advisory role from Alkermes, Array, AstraZeneca, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Idera, Immunocore, Incyte, Italfarmaco, Lunaphore, MedImmune, Merck, MSD, Nektar, Nouscom, Novartis, Oncosec, Pfizer, Pierre Fabre, Regeneron, Roche-Genentech, Sandoz, Sanofi, Seagen, Sun Pharma, Syndax, Takis, Ultimovacs, and 4SC; and travel support from MSD outside the submitted work. Riccardo Marconcini reports consulting fees from Incyte, La Roche, MSD, Novartis, and Pierre Fabre; honoraria from BMS, Ipsen, La Roche, MSD, Novartis, and Pierre Fabre; travel support from BMS, Ipsen, La Roche, MSD, Novartis, and Pierre Fabre; and participation in advisory boards for BMS, Ipsen, MSD, Novartis, and Pierre Fabre outside the submitted work. Michele Guida reports an advisory role for BMS, MSD, Novartis, and Pierre Fabre outside the submitted work. Michele Del Vecchio reports an advisory and consultant role for BMS, MSD, Novartis, Pierre Fabre, and Sanofi. Ilaria Gioia Marcon is an employee of Novartis Farma S.p.A. Paola Queirolo reports participation in advisory boards of BMS, Merck, MSD, Novartis, Pierre Fabre, Roche, Sanofi, and Sun Pharma. Massimo Aglietta, Paolo Fava, Gaetana Rinaldi, Maria Banzi, Rossana Gueli, Virginia Ferraresi, Marco Tucci, Giuseppe Tonini, and Giovanni Lo Re have declared no conflicts of interest.
: This study was designed, implemented, and reported in accordance with the Guidelines for Good Pharmacoepidemiology Practices (GPP) of the International Society for Pharmacoepidemiology (ISPE 2016), the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines, and ethical principles that are outlined in the Declaration of Helsinki.
: All patients provided written informed consent (not applicable for deceased patients).
: Not applicable.
: Not applicable.
: Not applicable.
: This study was designed and sponsored by Novartis Farma S.p.A. Data were collected and analyzed by the funder. All the authors were involved in the investigation, critically reviewed and drafted the manuscript, provided final approval, and agreed to be accountable for all aspects of the work. All the authors had full access to the study data and share final responsibility for the content of the report and the decision to submit for publication.